Harnessing Spatial Technologies to Identify Drug Targets, Enhance Biomarker Discovery, and Improve Translational Research to Develop Commercially Successful Drugs
Harnessing Spatial Technologies to Identify Drug Targets, Enhance Biomarker Discovery, and Improve Translational Research to Develop Commercially Successful Drugs
The past year saw a surge of investment into the Spatial Biology field with the recent Bruker acquisition of NanoString, and increased interest from biopharma into its potential to empower drug development, with many like AbbVie and GSK actively investing to update their labs to align with this.
It has never been a more exciting time to leverage Spatial Biology as the must-have tool for drug development, as more data emerges, and the different technologies undergo validation. However, the big questions of “how do you choose the right technology, how do you build the internal infrastructure to support this, and how can you build a business case to adopt the technology in a cost-effective and time-efficient way?” persists.
The 2nd Spatial Biology for Drug Development Summit returned and enabled your peers from the different functions to uncover practical, real-world case studies from biopharma to effectively apply spatial biology across drug discovery and development.
This conference is the only intimate, industry-focussed forum, where you can learn from the industry experts harnessing the different spatial technologies available to develop a gold standard and confidently empower your own drug development workflows to create better drugs.
A Snapshot of What was Covered:
Understand strategies to best apply spatial multiplex imaging to identify predictive biomarkers with BMS to refine patient stratification methods and enhance future clinical trial design
Discover Pfizer’s best practices to train machine learning models on spatial data to observe tissue patterns more accurately and gain better insight into disease progression and outcomes
Interrogate oncology and immunology disease biology by combining single-cell technology with spatial biology with Sanofi to ensure more accurate target identification and validation
Uncover how GSK implement spatial transcriptomics to gain in-depth insight into drug-induced reproductive toxicity, enabling more data-driven decision-making into their pipeline development
Hear insights from the Independence Blue Cross to gain an understanding of a payor’s stance on using spatial data to support translational drug development and the reimbursement process
Expert Speakers included:
Eugean Jiwanmall
Senior Research Analyst for Medical Policy & Technology Assessment
Independence Blue Cross
2024 Attendees Included:
What They Thought:
Expert Partners in 2024:
